Products
Opelkibart Biosimilar Antibody-Drug Conjugate (c-Kit) for Research
Cat No.: GMP-Bios-INN-1317
Anti-KIT/CD117 therapeutic antibody (Pre-made Opelkibart biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Opelkibart (development code MGTA-117) is an antibody-drug conjugate targeting KIT. It is developed by Heidelberg Pharma, Harvard University, Dianthus Therapeutics, and Magenta Therapeutics. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1317-1mg | 1mg | 4635 |
| GMP-Bios-INN-1317-10mg | 10mg | |
| GMP-Bios-INN-1317-100mg | 100mg | |
| GMP-Bios-INN-1317-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Opelkibart biosimilar, Whole mAb ADC, Anti-KIT/CD117 Antibody: Anti-CD117/c-Kit/KIT/Mast therapeutic antibody |
| INN Name | Opelkibart |
| Target | KIT/CD117 |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Heidelberg Pharma;Harvard University;Dianthus Therapeutics;Magenta Therapeutics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Acute myeloid leukaemia;Haemoglobinopathies;Lysosomal storage diseases;Myelodysplastic syndromes |
| Production | na |
| Development Tech | na |
